间充质干细胞双向调节肿瘤疾病

doi:10.3969/j.issn.2095-1396.2020.04.006

摘要/Abstract

摘要：

间充质干细胞（mesenchymal stem cells，MSCs）是具有强大增殖能力和多向分化潜在能力的祖细胞，根据来源不同，可以分为骨髓间充质干细胞、胎盘间充质干细胞、脐带间充质干细胞和脂肪间充质干细胞。MSCs有望成为用于细胞治疗和促进组织修复的候选细胞。然而，MSCs 在某些情况下对肿瘤细胞的促进作用也不能忽视。该文回顾近年来关于MSCs 双向调节肿瘤细胞的文献，从中探究引起肿瘤细胞的增殖，迁移，侵袭产生抑制或者促进作用机制和规律，为科学合理地开展MSCs 的临床试验提供参考。

关键词: 间充质干细胞, 肿瘤, 双向调节, 间充质干细胞载体

Abstract:

Mesenchymal stem cells （MSCs） are progenitors with strong proliferation and multi-differentiation potential. According to different sources，MSCs can be divided into bone marrow，placental，umbilical and fat mesenchymal stem cells. MSCs are promising candidates for cell-based therapies and for the promotion of tissue repair. However，the promotion effect of MSCs on tumor cells in some cases cannot be ignored. This paper reviews the recent literature on the bidirectional regulation of MSCs in tumor cells，and explores the mechanism and law of inhibiting or promoting the proliferation，migration and invasion of tumor cells，so as to provide reference for scientific and reasonable clinical trials of MSCs.

Key words: mesenchymal stem cells, tumor, dual-directional regulation, mesenchymal stem cell vector

中图分类号:

R979.1

引用本文

赵江豪, 崔世聪, 郭春燕. 间充质干细胞双向调节肿瘤疾病[J]. 神经药理学报, 2020, 10(4): 29-35.

ZHAO Jiang-hao, CUI Shi-cong, GUO Chun-yan. Bidirectional Adjusting Effects of Mesenchymal Stem Cells on Tumor Diseases[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 29-35.

使用本文

0
/ 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://actanp.hebeinu.edu.cn/CN/10.3969/j.issn.2095-1396.2020.04.006

http://actanp.hebeinu.edu.cn/CN/Y2020/V10/I4/29

参考文献

[1] 王萍, 马予洁, 路君, 等. 肿瘤相关间充质干细胞及其靶向治疗的研究进展[J]. 中华细胞与干细胞杂志, 2018, 8(01): 35-38.

[2] 徐应龙, 王坚. 间充质干细胞作为载体用于肿瘤治疗[J]. 第二军医大学学报, 2011, 00(09):1030-1034.

[3] Pietro Gentile, Simone Garcovich. Concise review: adipose-derived stem cells (ASCs) and adipocyte-secreted exosomal microRNA (A-SE-miR) modulate cancer growth and promote wound repair[J]. J Clin Med, 2019, 8(6): 855.

[4] Maria Giovanna Scioli, Gabriele Storti, Federico D'Amico, et al. Adipose-derived stem cells in cancer progression: New perspectives and opportunities[J]. Int J Mol Sci, 2019, 20(13): 3296.

[5] Roberta Armignacco, Giulia Cantini, Poli Giada, et al. The adipose stem cell as a novel metabolic actor in adrenocortical carcinoma progression: evidence from an in vitro tumor microenvironment crosstalk model[J]. Cancers (Basel), 2019, 11(12): 1931.

[6] Matthew A Lyes, Sturgis Payne, Paul Ferrell, et al. Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence[J]. Breast Cancer Res Treat, 2019, 174(2): 413-422.

[7] Rafael Schmid, Katharina Wolf, Jan W Robering, et al. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro[J]. BMC Cancer, 2018, 18(1): 1273.

[8] Wei-Lan Yeh, Cheng-Fang Tsai, Dar-Ren Chen. Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer[J]. Stem Cell Res Ther, 2017, 8(1): 177.

[9] Wang Tao, Yu Xi, Lin Jian, et al. Adipose-derived stem cells inhibited the proliferation of bladder tumor cells by S phase arrest and Wnt/β-catenin pathway[J]. Cell Reprogram, 2019, 21(6): 331-338.

[10] Masahiko Aoki, Kazuki Kakimoto, Masahiro Goto, et al. Novel therapeutic approach using drug-loaded adipose-derived stem cells for pancreatic cancer[J]. Sci Rep, 2019, 9(1): 17971.

[11] Cinzia Borghese, Naike Casagrande, Corona G, et al. Adipose-derived stem cells primed with paclitaxel inhibit ovarian cancer spheroid growth and overcome paclitaxel resistance[J]. Pharmaceutics, 2020, 12(5): 401.

[12] Lu Jui-hua, Peng Bou-yue, Chang Chun-chao, et al. Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine[J]. Cancers (Basel), 2018, 10(11): 446.

[13] Adriana Bajetto, Alessandra Pattarozzi, Alessandro Corsaro, et al. Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors[J]. Front Cell Neurosci, 2017, 11: 312.

[14] Yang Juan, Miao Ying-lei, Chang Ye-fei, et al. Condition medium of HepG-2 cells induces the transdifferentiation of human umbilical cord mesenchymal stem cells into cancerous mesenchymal stem cells[J]. Am J Transl Res, 2016, 8(8): 3429-3438.

[15] Xue Jian-guo, Zhu Yuan, Sun Zi-xuan, et al. Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness[J]. BMC Cancer, 2015, 15(1): 793.

[16] Li Tao, Zhang Jun, Zhang Jiahui, et al. Nicotine-enhanced stemness and epithelial-mesenchymal transition of human umbilical cord mesenchymal stem cells promote tumor formation and growth in nude mice[J]. Oncotarget, 2017, 9(1): 591-606.

[17] Meng Ming-yao, Li Lin, Wang Wen-ju, et al. Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo[J]. J Cancer Res Clin Oncol, 2019, 145(5): 1133-1146.

[18] Shen Ching-ju, Chan Te-fu, Chen Chien-chung, et al. Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis[J]. Oncotarget, 2016, 7(23): 34172-34179.

[19] Li Zhen-zhen, Ye Zhou, Zhang Xiao-long, et al. E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice[J]. Oncotarget, 2016, 7(32): 51815-51828.

[20] Dong Li-yang, Ding Chao, Zheng Tin-ging, et al. Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration[J]. Am J Transl Res, 2019, 11(11): 6989-6999.

[21] Li Xin, Liu Li-li, Yao Ju-lei, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles inhibit endometrial cancer cell proliferation and migration through delivery of exogenous miR-302a[J]. Stem Cells Int, 2019, 2019: 8108576.

[22] Yuan Lei, Liu Yu-qiong, Qu Yun-hui, et al. Exosomes derived from microRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression[J]. Front Oncol, 2019, 9: 1076.

[23] Mohamed Abumaree, Najlaa Alshehri, Almotery A, et al. Preconditioning human natural killer cells with chorionic villous mesenchymal stem cells stimulates their expression of inflammatory and anti-tumor molecules[J]. Stem Cell Res Ther, 2019, 10(1): 50.

[24] Alaa Tariq Alshareeda, Emad Rakha, Ayidah Alghwainem, et al. The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks[J]. PLoS One, 2018, 13(11): e0207593.

[25] Marta Magatti, Silvia De Munari, Elsa Vertua, et al. Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest[J]. J Cell Mol Med, 2012, 16(9): 2208-2218.

[26] Arianna Bonomi, Antonietta Silini, Elsa Vertua, et al. Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study[J]. Stem Cell Res Ther, 2015, 6(1):155.

[27] Hae Kyung Lee, Susan Finniss, Simona Cazacu, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal[J]. Oncotarget, 2013, 4(2): 346-361.

[28] Zheng Lan, Zhang Dong-mei, Chen Xian-cheng, et al. Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer[J]. PLoS One, 2012, 7(7): e39119.

[29] Zhang Dong-mei, Zheng Lan, Shi Hua-shan, et al. Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer[J]. Int J Med Sci, 2014, 11(9): 870-879.

[30] Zhang Yan-na, Duan Xiao-gang, Zhang Wen-hui, et al. Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiation[J]. Onco Targets Ther, 2016, 9: 1425-1436.

[31] Paola Cafforio, Luigi Viggiano, Francesco Mannavola, et al. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo[J]. Stem Cell Res Ther, 2017, 8(1): 206.

[32] Yang Jiany-ing, Lv Kui, Sun Jun-feng, et al. Anti-tumor effects of engineered mesenchymal stem cells in colon cancer model[J]. Cancer Manag Res, 2019, 11: 8443-8450.

[33] Chen Dan-dan, Tang Ping, Liu Lin-xiang, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway[J]. Cell Cycle, 2018, 17(7): 858-867.

[34] Mi Fei, Gong Lian-sheng. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma[J]. Biosci Rep, 2017, 37(4): BSR20170181.

[35] Chen Bin, Yu Jing, Wang Qian-qian, et al. Human Bone Marrow Mesenchymal Stem Cells Promote Gastric Cancer Growth via Regulating c-Myc[J]. Stem Cells Int, 2018, 2018: 9501747.

[36] Lu Li, Chen Guo-hu, Yang Jing-jing, et al. Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway[J]. Biomed Pharmacother, 2019, 112: 108625.

[37] Qi Jin, Zhou Ya-li, Jiao Zuo-yi, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth through hedgehog signaling pathway[J]. Cell Physiol Biochem, 2017, 42(6): 2242-2254.

[38] Huang Yao, Liu Wei, He Bing, et al. Exosomes derived from bone marrow mesenchymal stem cells promote osteosarcoma development by activating oncogenic autophagy[J]. J Bone Oncol, 2020, 21: 100280.

[39] Ma Min, Chen Shi-lin, Liu Zhuo, et al. miRNA-221 of exosomes originating from bone marrow mesenchymal stem cells promotes oncogenic activity in gastric cancer[J]. Onco Targets Ther, 2017, 10: 4161-4171.

[40] Wu Dong-mei, Wen Xin, Han Xin-rui, et al. Bone marrow mesenchymal stem cell-derived exosomal microRNA-126-3p inhibits pancreatic cancer development by targeting ADAM9[J]. Mol Ther Nucleic Acids, 2019, 16: 229-245.

[41] Shang Song, Wang Jin-feng, Chen Shi-lin, et al. Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer[J]. Cancer Med, 2019, 8(18): 7728-7740.

[42] Jiang Shuang-jian, Mo Cheng-qiang, Guo Sheng-jie, et al. Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the progression of prostate cancer through suppression of RHPN2[J]. J Exp Clin Cancer Res, 2019, 38(1): 495.

[43] Wang Ai-hong, Zhou Xiao-yan, Zhao Ju-mei, et al. Therapeutic effects of bone marrow mesenchymal stem cells expressing interleukin-12 in mice bearing malignant ascites tumor[J]. Int J Clin Exp Med, 2015, 8(9): 15840-15845.

[44] Sabine Galland, Ivan Stamenkovic. Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression[J]. J Pathol, 2020, 250(5): 555-572.

[45] Pan Zhao-ji, Tian Yi-qing, Niu Guo-ping, et al. The emerging role of GC-MSCs in the gastric cancer microenvironment: from tumor to tumor immunity[J]. Stem Cells Int, 2019, 2019(12): 8071842.

编辑推荐

Metrics

阅读次数

全文

摘要

摘要
参考文献
相关文章
编辑推荐
Metrics

回顶部